The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants
Open accessAbstract
Background: The current guidelines of statins for primary cardiovascular disease (CVD) prevention were based on results from systematic reviews and meta‐analyses that suffer from limitations. Methods: We searched in PubMed for existing systematic reviews and individual open‐label or double‐blinded randomized controlled trials that compared a statin with a placebo or another, which were published in English until January 01, 2018. We performed a random‐effect pairwise meta‐analysis of all statins as a class and network meta‐analysis for the specific statins on different benefit and harm outcomes. Results: In the pairwise meta‐analyses, statins as a class showed statistically significant risk reductions on non‐fatal MI (risk ratio [RR] 0.62, 95% CI 0.53–0.72), CVD mortality (RR 0.80, 0.71–0.91), all‐cause mortality (RR 0.89, 0.85–0.93), non‐fatal stroke (RR 0.83, 0.75–0.92), unstable angina (RR 0.75, 0.63–0.91), and composite major cardiovascular events (RR 0.74, 0.67–0.81). Statins increased statistically significantly relative and absolute risks of myopathy (RR 1.08, 1.01–1.15; Risk difference [RD] 13, 2–24 per 10,000 person‐years); renal dysfunction (RR 1.12, 1.00–1.26; RD 16, 0–36 per 10,000 person‐years); and hepatic dysfunction (RR 1.16, 1.02–1.31; RD 8, 1–16 per 10,000 person‐years). The drug‐level network meta‐analyses showed that atorvastatin and rosuvastatin were most effective in reducing CVD events while atorvastatin appeared to have the best safety profile. Conclusions: All statins showed statistically significant risk reduction of CVD and all‐cause mortality in primary prevention populations while increasing the risk for some harm risks. However, the benefit‐harm profile differed by statin type. A quantitative assessment of the benefit‐harm balance is thus needed since meta‐analyses alone are insufficient to inform whether statins provide net benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“The median of the proportion of participants with type 2 diabetes was 14% (3-95); hypertension, 42% (27-84); male sex, 61% (48-77); smoker, 28% (17-45) and white Caucasian, 92% (83-95).”
BackgroundStatins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Cited by
Periodontitis and cardiovascular diseases: Consensus report
Sanz, M., Marco del Castillo, A., Jepsen, S., Gonzalez‐Juanatey, J. R., D’Aiuto, F., Bouchard, P., Chapple, I., Dietrich, T., Gotsman, I., Graziani, F., et al. (2020) · Journal of Clinical Periodontology · doi:10.1111/jcpe.13189 · Cited by 1,482
Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage
Diener, H.-C., & Hankey, G. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.072 · Cited by 364
Periodontitis and Cardiovascular Diseases. Consensus Report
Sanz, M., Del Castillo, A. M., Jepsen, S., Gonzalez-Juanatey, J. R., D’Aiuto, F., Bouchard, P., Chapple, I., Dietrich, T., Gotsman, I., Graziani, F., et al. (2020) · Global Heart · doi:10.5334/gh.400 · Cited by 271
Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights
Stein, R., Ferrari, F., & Scolari, F. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1161-5 · Cited by 83
An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy
Etemad, L., Salmasi, Z., Moosavian Kalat, S. A., Moshiri, M., Zamanian, J., Kesharwani, P., & Sahebkar, A. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116572 · Cited by 18
Metadata
- Authors
- Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A.
- Venue
- American Heart Journal
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 210
- Pages
- 18-28
- ISSN
- 0002-8703 (ISSN-L)
- OpenAlex
- W2909436318
- Cited by
- 178
- References
- 21
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. https://app.cochat.ai/papers/10.1016/j.ahj.2018.12.007
- The paper
- Yebyo, H. G., Aschmann, H. E., Kaufmann, M., & Puhan, M. A. (2019). Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal. https://doi.org/10.1016/j.ahj.2018.12.007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.